ghk-cu subcutaneous injection clinical trial ghk cu dosing protocol administration GHK-Cu Dosage and Protocol: A Medical Provider's Guide to the 30 GHK-Cu vs NAD+: Which Longevity
Description
Reduced joint pain and improved mobility
doi: 10.1016/j.biopha.2022.113528 256 NeyL-MWipplingerMGrossmannMEngertNWegnerVDMosigAS
[PubMed] [Google Scholar] 4.Hill JR, Lanier ST, Brogan DM, Dy CJ
Given the striking decrease of 55% of cells entering the S-phase of the cell cycle upon treatment with 2 ng/mL and 10 ng/mL of BPC 157 and decreased ERK phosphorylation, it was suggested that BPC 157 acts as an antimitogenic agent by preventing ERK phosphorylation and the propagation of the mitogenic signal via the MAPK signaling cascade, triggered by VEGF [95]
